neurology

In the Lab By Elizabeth Cooney

A ‘sniff test’ signals consciousness after a brain injury, study shows

Biotech By Kate Sheridan

Two companies bet on ‘chemogenetics’ to sidestep challenges with neurological drug development 

First Opinion By Meredith O'Brien

A chronic illness conundrum: Should I tell my employer about my MS?

First Opinion By Keita Mori

The U.S. needs a nationwide registry for traumatic brain injury

In the Lab By Sharon Begley

They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why

Pharmalot By Ed Silverman

ICER, the controversial cost-effectiveness watchdog, reverses course on two migraine drugs

Pharmalot By Ed Silverman

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

First Opinion By Donna Jackson Nakazawa

Microglia: a new target in the brain for depression, Alzheimer’s, and more?

Biotech By Matthew Herper

A venture firm warms to funding neuroscience

Pharmalot By Ed Silverman

High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’

Biotech By Jonathan Saltzman — Boston Globe

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

Biotech By Jonathan Saltzman — Boston Globe

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

Health By Felice J. Freyer — Boston Globe

After Ice Bucket campaign, researchers have optimism about insights into ALS puzzle

In the Lab By Sharon Begley

Research using brains-in-a-dish forces a radical rethinking of Huntington’s disease

Health By Andrew Joseph

A clinical trial for Huntington’s opens the door to hope for some patients. Only so many can get in

In the Lab By Elizabeth Cooney

Warning: Swimming and deep brain stimulation do not mix

Pharmalot By Ed Silverman

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

In the Lab By Sharon Begley

Long-neglected gene plays a bigger role in Alzheimer’s than suspected, study shows

Biotech By Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

In the Lab By Sharon Begley

She was destined to get early Alzheimer’s, but didn’t. Did a rare mutation protect her?

Health By Jonathan Saltzman — Boston Globe

Can a simple eye exam replace costly and invasive Alzheimer’s diagnostic procedures?

Health By Andrew Joseph

Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again

Special Report By Sharon Begley

Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide

Biotech By Jonathan Saltzman — Boston Globe

Vertex takes on Huntington’s disease in deal with Ribometrix

First Opinion By Munro Cullum

Is football bad for the brain? We know little about the long-term effects of concussions